Literature DB >> 17555142

Uterine fibroid tumors: diagnosis and treatment.

Patricia Evans1, Susan Brunsell.   

Abstract

The incidence of uterine fibroid tumors increases as women grow older, and they may occur in more than 30 percent of women 40 to 60 years of age. Risk factors include nulliparity, obesity, family history, black race, and hypertension. Many tumors are asymptomatic and may be diagnosed incidentally. Although a causal relationship has not been established, fibroid tumors are associated with menorrhagia, pelvic pain, pelvic or urinary obstructive symptoms, infertility, and pregnancy loss. Transvaginal ultrasonography, magnetic resonance imaging, sonohysterography, and hysteroscopy are available to evaluate the size and position of tumors. Ultrasonography should be used initially because it is the least invasive and most cost-effective investigation. Treatment options include hysterectomy, myomectomy, uterine artery embolization, myolysis, and medical therapy. Treatment must be individualized based on such considerations as the presence and severity of symptoms, the patient's desire for definitive treatment, the desire to preserve childbearing capacity, the importance of uterine preservation, infertility related to uterine cavity distortions, and previous pregnancy complications related to fibroid tumors.

Entities:  

Mesh:

Year:  2007        PMID: 17555142

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  25 in total

1.  Uterine artery embolization versus abdominal myomectomy: a long-term clinical outcome comparison.

Authors:  Anand Narayan; Adrea S Lee; George P Kuo; Neil Powe; Hyun S Kim
Journal:  J Vasc Interv Radiol       Date:  2010-05-31       Impact factor: 3.464

2.  Development of an electronic daily uterine fibroid symptom diary.

Authors:  Linda S Deal; Valerie S L Williams; Sheri E Fehnel
Journal:  Patient       Date:  2011       Impact factor: 3.883

3.  Uterine Leiomyomata in South Western Nigeria: a clinical study of presentations and management outcome.

Authors:  F O Okogbo; O C Ezechi; O M Loto; P M Ezeobi
Journal:  Afr Health Sci       Date:  2011-06       Impact factor: 0.927

4.  Comparison of the Perioperative Outcomes of a Vessel Sealing Instrument-Assisted Technique with a Conventional Technique in Abdominal Myomectomy.

Authors:  Mustafa Ulubay; Mustafa Öztürk; Fahri Burçin Firatligil; Ulas Fidan; Ugur Keskin; Murat Dede; Müfit Cemal Yenen
Journal:  J Clin Diagn Res       Date:  2016-01-01

5.  Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.

Authors:  Hen Prizant; Aritro Sen; Allison Light; Sung-Nam Cho; Francesco J DeMayo; John P Lydon; Stephen R Hammes
Journal:  Mol Endocrinol       Date:  2013-07-02

6.  Nicotinamide adenine dinucleotide phosphate oxidase is differentially regulated in normal myometrium versus leiomyoma.

Authors:  Nicole M Fletcher; Mohammed G Saed; Suleiman Abuanzeh; Husam M Abu-Soud; Ayman Al-Hendy; Michael P Diamond; Ghassan M Saed
Journal:  Reprod Sci       Date:  2014-02-11       Impact factor: 3.060

Review 7.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

8.  Uterine fibroids are characterized by an impaired antioxidant cellular system: potential role of hypoxia in the pathophysiology of uterine fibroids.

Authors:  N M Fletcher; M G Saed; H M Abu-Soud; A Al-Hendy; M P Diamond; G M Saed
Journal:  J Assist Reprod Genet       Date:  2013-06-30       Impact factor: 3.412

Review 9.  Ulipristal acetate: in uterine fibroids.

Authors:  Jamie D Croxtall
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

Review 10.  Macrophages and Immune Responses in Uterine Fibroids.

Authors:  Alessandro Zannotti; Stefania Greco; Pamela Pellegrino; Federica Giantomassi; Giovanni Delli Carpini; Gaia Goteri; Andrea Ciavattini; Pasquapina Ciarmela
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.